Skip to content

Autonomy Bio

6 viewers · 30d

Total raised

$17.0M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $17.0M
ROUNDS
1
INVESTORS
8
FOUNDED
2024
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Autonomy Bio Inc. is an innovative biotechnology firm focused on advancing RNA-based therapeutics specifically designed to address challenging diseases, with a strong emphasis on oncology and infectious diseases. Leveraging proprietary technology, the company is committed to enhancing the precision and effectiveness of treatments to improve patient outcomes for complex conditions.

What sets it apart

Autonomy Bio stands out with its proprietary encrypted RNA technology that enables targeted therapeutic effects only in diseased cells, minimizing side effects on healthy cells.

Funding history

1 round
EquityMar 17, 2025
Form D
+$17.0M$17.0M total

Latest SEC filings

via EDGAR · CIK 0002063071
Form D · Mar 17, 2025View on EDGAR

Products

1 tracked

Encrypted RNA (encRNA)

RNA therapeutics

EncRNA is a groundbreaking class of RNA therapeutics engineered for precision targeting of malignant cells, ensuring that therapeutic interventions activate specifically within cancer cells. This mechanism aims to enhance treatment efficacy while reducing the risk of toxicity associated with standard therapies.

  • Precision targeting of diseased cells
  • Cancer-activated therapeutic protein translation
  • Minimized side effects on healthy tissue

Links

WebsiteSEC EDGAR filings